Janssen's Lebowitz On J&J's Oncology Expansion Plans Outside Of Hematology
Executive Summary
Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's next big ambitions in lung, bladder and prostate cancer.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.
No Way To Go But Grow: J&J Outlines Plans To Become A $60bn Pharma In 2025
Management outlined its growth strategy to investors, highlighting plans to file 14 novel drugs with more than $1bn in peak sales by 2025.
J&J’s Consumer Health Spinout Plan Surprises, But Seen As Sensible
Analysts say the pharma’s plan would separate out a unit with less growth and lower margins – and some predict a further breakup of the pharma and medical device units.